Rinatabart sesutecan is a highly homogeneous antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα). Rinatabart sesutecan consists of a humanized antibody targeting FRα, a hydrophilic cleavable linker, and the topoisomerase I inhibitor eribulin as the payload. It is primarily used for the targeted treatment and mechanistic research of folate receptor-positive solid tumors.